MGNX MacroGenics, Inc. Stock Quote

MGNX [NASD]

Index	-	P/E	-	EPS (ttm)	-3.13	Insider Own	0.20%	Shs Outstand	54.46M	Perf Week	0.34%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-2.10	Insider Trans	-46.07%	Shs Float	53.32M	Perf Month	-16.74%
Income	-158.00M	PEG	-	EPS next Q	-0.61	Inst Own	97.30%	Short Float	6.94%	Perf Quarter	-16.06%
Sales	77.40M	P/S	15.35	EPS this Y	24.60%	Inst Trans	0.22%	Short Ratio	5.43	Perf Half Y	-26.39%
Book/sh	5.35	P/B	3.85	EPS next Y	34.40%	ROA	-49.40%	Target Price	30.80	Perf Year	77.65%
Cash/sh	4.86	P/C	4.23	EPS next 5Y	-	ROE	-65.80%	52W Range	4.04 - 32.18	Perf YTD	-9.93%
Dividend	-	P/FCF	-	EPS past 5Y	-17.70%	ROI	-76.80%	52W High	-36.02%	Beta	2.25
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	6.10%	Gross Margin	-	52W Low	409.65%	ATR	1.37
Employees	384	Current Ratio	6.20	Sales Q/Q	-2.10%	Oper. Margin	-	RSI (14)	36.30	Volatility	3.69% 6.21%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	27.50%	Profit Margin	-	Rel Volume	0.68	Prev Close	20.62
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 AMC	Payout	-	Avg Volume	680.81K	Price	20.59
Recom	2.00	SMA20	-9.92%	SMA50	-8.21%	SMA200	-8.56%	Volume	463,860	Change	-0.15%

Dec-22-20

Resumed

H.C. Wainwright

Buy

$36

Aug-03-20

Downgrade

Citigroup

Buy → Neutral

$25 → $26

Jun-01-20

Upgrade

Guggenheim

Neutral → Buy

May-26-20

Reiterated

H.C. Wainwright

Buy

$22 → $40

Mar-04-20

Initiated

Barclays

Underweight

Dec-19-19

Initiated

Cantor Fitzgerald

Overweight

Dec-18-19

Initiated

Cantor Fitzgerald

Overweight

Nov-21-19

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$17 → $6

Nov-20-19

Resumed

Guggenheim

Neutral

May-03-19

Upgrade

Wedbush

Neutral → Outperform

$26

Apr-12-19

Initiated

Guggenheim

Neutral

Feb-07-19

Upgrade

Citigroup

Sell → Buy

Feb-07-19

Downgrade

Wedbush

Outperform → Neutral

Feb-06-19

Upgrade

Raymond James

Underperform → Mkt Perform

Feb-04-19

Downgrade

Citigroup

Neutral → Sell

$10

Dec-10-18

Downgrade

Raymond James

Outperform → Underperform

Sep-10-18

Resumed

BTIG Research

Buy

$30

May-31-18

Initiated

Evercore ISI

Outperform

$33

Mar-05-18

Initiated

H.C. Wainwright

Buy

$38

Mar-31-17

Initiated

Raymond James

Outperform

$26

Jan-11-21 08:45AM	MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire
Dec-22-20 11:52PM	Downgrade: Here's How Analysts See MacroGenics, Inc. (NASDAQ:MGNX) Performing In The Near Term Simply Wall St.
11:35AM	MacroGenics Announces MGD019 Publication in Cell Reports Medicine GlobeNewswire
Dec-18-20 07:30AM	MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule GlobeNewswire
Dec-17-20 03:47PM	Why MacroGenics Stock Soared Then Sank Today Motley Fool
08:10AM	The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga
Dec-16-20 08:15PM	Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer GlobeNewswire
04:30PM	MacroGenics Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer GlobeNewswire
Dec-13-20 09:14AM	The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics Benzinga
Dec-07-20 07:30AM	MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting GlobeNewswire
Dec-06-20 01:00PM	MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting GlobeNewswire
Dec-01-20 08:08AM	The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga
Nov-30-20 04:30PM	MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab GlobeNewswire
07:30AM	MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte GlobeNewswire
Nov-09-20 05:00PM	MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-20 08:06AM	MacroGenics, Inc. (NASDAQ:MGNX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St. -5.76%
Nov-05-20 04:33AM	MacroGenics (MGNX) Q3 2020 Earnings Call Transcript Motley Fool
Nov-04-20 06:05PM	MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.25%
04:27PM	Macrogenics: Q3 Earnings Insights Benzinga
04:01PM	MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results GlobeNewswire
02:30PM	MacroGenics, Inc. to Host Earnings Call ACCESSWIRE
02:30PM	MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020 GlobeNewswire
Oct-28-20 04:30PM	MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call GlobeNewswire
12:32PM	Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-15-20 04:30PM	MacroGenics Announces Flotetuzumab Publication in Blood Advances GlobeNewswire
Oct-05-20 11:19AM	Hedge Funds Are Coming Back To MacroGenics Inc (MGNX) Insider Monkey +7.13%
Sep-23-20 07:15AM	MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics GlobeNewswire
Sep-22-20 04:30PM	MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood GlobeNewswire -6.29%
Sep-21-20 07:30AM	MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte GlobeNewswire -12.91%
Sep-20-20 09:10AM	MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020 GlobeNewswire
Sep-16-20 10:37AM	If You Had Bought MacroGenics (NASDAQ:MGNX) Stock A Year Ago, You Could Pocket A 120% Gain Today Simply Wall St.
Sep-03-20 07:30AM	MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-05-20 04:30PM	MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-02-20 10:21AM	News Flash: Analysts Just Made A Notable Upgrade To Their MacroGenics, Inc. (NASDAQ:MGNX) Forecasts Simply Wall St.
Aug-01-20 03:03AM	MacroGenics (MGNX) Q2 2020 Earnings Call Transcript Motley Fool
Jul-31-20 06:55AM	Is MacroGenics, Inc. (NASDAQ:MGNX) Trading At A 37% Discount? Simply Wall St. -5.05%
Jul-30-20 06:40PM	MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results GlobeNewswire
Jul-23-20 07:30AM	MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call GlobeNewswire
Jul-22-20 12:32PM	Earnings Preview: MacroGenics (MGNX) Q2 Earnings Expected to Decline Zacks
Jul-09-20 06:43PM	MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer GlobeNewswire
05:22PM	Here's Why MacroGenics Jumped 156.6% in the First Half of 2020 Motley Fool
Jun-27-20 09:28PM	Is MacroGenics Inc (MGNX) A Good Stock To Buy? Insider Monkey
Jun-22-20 09:00AM	MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting GlobeNewswire
Jun-16-20 07:30AM	MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer GlobeNewswire
Jun-05-20 07:30AM	MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer GlobeNewswire
Jun-03-20 04:05PM	MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia GlobeNewswire
May-29-20 12:45PM	Here's Why MacroGenics Is Tumbling 17.3% Today Motley Fool -16.35%
May-28-20 07:30AM	MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer GlobeNewswire
May-27-20 07:30AM	MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia GlobeNewswire
03:50AM	Edited Transcript of MGNX earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-21-20 04:05PM	MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO GlobeNewswire
May-18-20 07:06AM	What You Need To Know About The MacroGenics, Inc. (NASDAQ:MGNX) Analyst Downgrade Today Simply Wall St.
May-13-20 05:10PM	MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting GlobeNewswire
May-12-20 08:40AM	Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock? Zacks
May-11-20 04:37PM	Why MacroGenics Stock Jumped 29% Today Motley Fool +29.40%
11:14AM	Optimism Runs High for MacroGenics GuruFocus.com
06:29AM	3 Small-Cap Biotech Stocks That Surged Last Week Motley Fool
May-08-20 08:10AM	Why MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Pay Matters To You Simply Wall St.
07:34AM	Analysts Have Made A Financial Statement On MacroGenics, Inc.'s (NASDAQ:MGNX) First-Quarter Report Simply Wall St.
May-06-20 03:01PM	Macrogenics Inc (MGNX) Q1 2020 Earnings Call Transcript Motley Fool +230.92%
01:24PM	Here's Why MacroGenics Stock Is Skyrocketing 171% Today Motley Fool
May-05-20 06:45PM	MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates Zacks +6.29%
04:01PM	MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results GlobeNewswire
08:36AM	Trump Pushes for US-Made Medical Products: 4 Winners Zacks
Apr-29-20 04:01PM	MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting GlobeNewswire
Apr-28-20 04:01PM	MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format GlobeNewswire
07:30AM	MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call GlobeNewswire
Apr-27-20 12:05AM	MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting GlobeNewswire
Apr-20-20 09:01AM	Part of Washington Convention Center to become field hospital for COVID-19 patients American City Business Journals +8.53%
Apr-17-20 08:54AM	Northam requests more federal aid, Montgomery County steps up PPE funding American City Business Journals +24.04%
Mar-16-20 06:16PM	These Greater Washington firms took the biggest dives Monday on Wall Street American City Business Journals -28.00%
Mar-10-20 01:50AM	Edited Transcript of MGNX earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents +10.70%
Mar-04-20 05:00PM	MacroGenics Announces Departure of Chief Medical Officer GlobeNewswire
Mar-02-20 08:45AM	These local companies have taken the biggest hits on Wall Street during current sell-off American City Business Journals
Feb-27-20 10:30AM	MacroGenics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St. -15.65%
07:30AM	MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-25-20 04:01PM	MacroGenics Provides Update on Corporate Progress and 2019 Financial Results GlobeNewswire
Feb-24-20 02:48PM	Some MacroGenics (NASDAQ:MGNX) Shareholders Have Copped A Big 67% Share Price Drop Simply Wall St.
Feb-13-20 07:30AM	MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call GlobeNewswire
Feb-10-20 07:30AM	MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire +5.78%
Jan-14-20 03:12PM	Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech American City Business Journals
Jan-13-20 07:30AM	MacroGenics to Present at the J.P. Morgan Healthcare Conference GlobeNewswire
Jan-09-20 04:30PM	MacroGenics Outlines Corporate Priorities for 2020 GlobeNewswire
Jan-06-20 05:14PM	Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug. American City Business Journals
Dec-19-19 12:00PM	MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA GlobeNewswire
Dec-11-19 10:00AM	MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium GlobeNewswire
Dec-09-19 03:05PM	MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting GlobeNewswire
Dec-07-19 08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Nov-15-19 12:02PM	We Think MacroGenics (NASDAQ:MGNX) Needs To Drive Business Growth Carefully Simply Wall St.
Nov-13-19 04:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. - MGNX ACCESSWIRE
Nov-12-19 01:45PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SNDL, MGNX and OLLI ACCESSWIRE
12:45PM	FILING FIRM ANNOUNCES DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:59AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MGNX, OSTK, RUHN and REZI GlobeNewswire
10:29AM	TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:00AM	DEADLINE ALERT - MacroGenics, Inc. (MGNX) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: November 12, 2019 PR Newswire
09:36AM	CLASS ACTION UPDATE for SNDL, DBX, MGNX and WTRH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
07:37AM	MacroGenics Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MacroGenics, Inc. To Contact The Firm Newsfile
03:29AM	Edited Transcript of MGNX earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
02:00AM	MGNX DEADLINE TODAY: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts MacroGenics (MGNX) Investors of Todays Deadline to Move for Lead Plaintiff ACCESSWIRE

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. MacroGenics, Inc. has strategic collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Risser Eric Blasius	Sr VP & Chief Business Officer	Dec 29	Option Exercise	1.51	500	755	44,968	Dec 30 04:05 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Dec 29	Sale	24.10	500	12,050	44,468	Dec 30 04:05 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Nov 30	Option Exercise	1.51	500	755	44,968	Dec 01 04:15 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Nov 30	Sale	23.35	500	11,675	44,468	Dec 01 04:15 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Oct 28	Option Exercise	1.51	1,500	2,265	45,968	Oct 29 07:52 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Oct 28	Sale	20.69	1,500	31,035	44,468	Oct 29 07:52 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Sep 28	Option Exercise	1.51	500	755	44,968	Sep 29 04:44 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Sep 28	Sale	25.33	500	12,665	44,468	Sep 29 04:44 PM
Bonvini Ezio	Sr VP, Research & CSO	Sep 18	Sale	32.00	18,339	586,848	83,807	Sep 21 04:51 PM
Bonvini Ezio	Sr VP, Research & CSO	Sep 17	Sale	29.88	44,512	1,330,019	102,146	Sep 21 04:51 PM
Galbraith Kenneth	Director	Sep 09	Option Exercise	17.38	20,773	361,103	13,849	Sep 10 04:44 PM
Galbraith Kenneth	Director	Sep 09	Sale	27.11	20,773	563,156	0	Sep 10 04:44 PM
Spitznagel Thomas	Sr VP, BPD & Manufacturing	Aug 20	Option Exercise	7.51	7,500	56,325	7,500	Aug 21 04:05 PM
Spitznagel Thomas	Sr VP, BPD & Manufacturing	Aug 20	Sale	26.87	7,500	201,525	0	Aug 21 04:05 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Jul 27	Option Exercise	1.45	4,489	6,500	48,468	Jul 28 05:12 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Jul 27	Sale	25.47	4,489	114,319	44,468	Jul 28 05:12 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Jul 02	Option Exercise	1.51	3,100	4,681	47,568	Jul 06 04:25 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Jul 02	Sale	30.00	3,100	93,000	44,468	Jul 06 04:25 PM
Peters Jeffrey Stuart	General Counsel	Jul 02	Sale	30.00	202	6,060	0	Jul 06 04:25 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Jun 24	Option Exercise	0.94	500	470	44,968	Jun 25 04:57 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Jun 24	Sale	28.49	500	14,245	44,468	Jun 25 04:57 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	May 26	Option Exercise	0.94	500	470	44,968	May 27 04:43 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	May 26	Sale	26.59	500	13,295	44,468	May 27 04:43 PM
Spitznagel Thomas	Sr VP, BPD & Manufacturing	May 20	Option Exercise	7.51	7,500	56,325	7,500	May 21 07:44 PM
Spitznagel Thomas	Sr VP, BPD & Manufacturing	May 20	Sale	25.30	7,500	189,750	0	May 21 07:44 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	May 06	Option Exercise	1.47	8,032	11,843	52,500	May 07 04:22 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	May 06	Sale	20.95	8,032	168,300	44,468	May 07 04:22 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Apr 16	Option Exercise	0.94	6,000	5,640	44,468	Apr 17 04:11 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Mar 13	Option Exercise	0.94	6,000	5,640	38,468	Mar 17 04:09 PM
Koenig Scott	President and CEO	Mar 11	Option Exercise	0.94	133,163	125,173	943,103	Mar 13 04:15 PM
Karrels James	SVP, CFO and Secretary	Mar 06	Option Exercise	0.94	4,473	4,205	152,460	Mar 09 04:39 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Feb 20	Option Exercise	0.94	500	470	32,968	Feb 21 04:44 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Feb 20	Sale	10.84	500	5,420	32,468	Feb 21 04:44 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Feb 05	Option Exercise	0.94	623	586	33,091	Feb 06 04:41 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Feb 05	Sale	10.00	623	6,230	32,468	Feb 06 04:41 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Feb 04	Option Exercise	0.94	30	28	32,498	Feb 06 04:41 PM
Risser Eric Blasius	Sr VP & Chief Business Officer	Feb 04	Sale	10.00	30	300	32,468	Feb 06 04:41 PM
Karrels James	SVP, CFO and Secretary	Jan 30	Option Exercise	0.94	12,500	11,750	147,987	Jan 31 04:45 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience